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We are grateful for the opportunity to respond to the
comments of Viljoen et al.1
The failure of some of their patients to acidify their
urine to a pHo5.3 (the threshold pH described by Wrong
and Davies in the original report of the ‘short NH4Cl
test’2) does not come as a major surprise. It is notable that
Viljoen used the ‘old’ version of the fludrocortisone/
furosemide (Fþ F) test in which fludrocortisone is taken
the preceding night. In an earlier brief report,3 we had
indicated that the ‘old’ Fþ F test appeared to be satis-
factory, when compared with the ‘NH4Cl test’,
2 in a group
of control (healthy) subjects. However, subsequent studies
in our laboratory found that it was not 100% reliable.
For this reason, we abandoned the ‘old’ test and switched
to the ‘new’ Fþ F test, as described in our recent paper,4
in which fludrocortisone and furosemide are given
simultaneously.
Despite Viljoen’s comment concerning the half-life of
fludrocortisone, this modification of the protocol is not a
trivial one. Mounting evidence has emphasized the rapid,
nongenomic properties of mineralocorticoid to stimulate
sodium reabsorption in principal cells (thereby increasing
lumen negativity and indirectly stimulating Hþ secretion)
and to stimulate HþATPase directly in intercalated cells.
ENaC activity in cortical collecting duct principal cells is
increased within 2 min of aldosterone administration,5
transport by basolateral Naþ ,KþATPase is increased
within 30 min,6 and HþATPase activity is increased within
15 min.7 To have these early effects operating at a time
when the distal delivery of sodium has been maximized
by treatment with furosemide may be crucial for the
reliability of the technique in reducing urine pH.
A secondary advantage of the ‘new’ Fþ F test, with
simultaneous dosing of the two drugs on the morning of
the test itself, is that it eliminates the possibility of patient
noncompliance in taking fludrocortisone the preceding
night, a concern that is perhaps heightened owing to the
possibility of sensorineural deafness in some of the
patients.8
Finally, we agree completely that the ‘new’ form of the
test needs rigorous assessment in a variety of patient
subgroups. Although no figures are given in the paper cited
by Viljoen,9 the high prevalence of urinary acidification
defects in stone formers is well known. We have been using
the new Fþ F test routinely as a screening test in our
patients (many of whom are stone formers) for some time.
To date, in each instance in which the Fþ F test has failed
to acidify the patient’s urine despite an absence of other
clinical features consistent with a diagnosis of distal renal
tubular acidosis (e.g., a family history or the presence of
autoimmune disease), a follow-up NH4Cl test has con-
firmed the result. The more we use the new test, the
more confidence we place in it as a screening tool for
distal renal tubular acidosis. It would be of interest to
see how the stone formers in Viljoen’s study respond to
this test.
1. Viljoen et al. Simultaneous fludrocortisone and furosemide for
assessment of urinary acidification. Kidney Int 2007 (in press).
2. Wrong O, Davies HEF. The excretion of acid in renal disease. Q J Med
1959; 28: 259–313.
3. Walter SJ, Shirley DG, Unwin RJ, Wrong OM. Assessment of urinary
acidification. Kidney Int 1997; 52: 2092.
4. Walsh SB, Shirley DG, Wrong OM, Unwin RJ. Urinary acidification
assessed by simultaneous furosemide and fludrocortisone treatment: an
alternative to ammonium chloride. Kidney Int 2007; 71: 1310–1316.
5. Zhou ZH, Bubien JK. Nongenomic regulation of ENaC by aldosterone.
Am J Physiol Cell Physiol 2001; 281: C1118–C1130.
6. Fujii Y, Takemoto F, Katz AI. Early effects of aldosterone on Na-K pump
in rat cortical collecting tubules. Am J Physiol 1990; 259: F40–F50.
7. Winter C, Schulz N, Giebisch G et al. Nongenomic stimulation of vacuolar
H+-ATPases in intercalated renal tubule cells by aldosterone. Proc Natl
Acad Sci USA 2004; 101: 2636–2641.
8. Karet FE, Finberg KE, Nayir A et al. Mutations in the gene encoding B1
subunit of H+-ATPase cause renal tubular acidosis with sensorineural
deafness. Nat Genet 1999; 21: 84–90.
9. Reynolds TM. Chemical pathology clinical investigation and
management of nephrolithiasis. J Clin Pathol 2005; 58: 134–140.
DG Shirley1, SB Walsh1, OM Wrong1 and RJ Unwin1
1Department of Physiology and the Centre for Nephrology, University College
London, London, UK
Correspondence: SB Walsh, Department of Physiology and the Centre for
Nephrology, University College London, Hampstead Campus, Rowland Hill
Street, London NW3 2PF, UK. E-mail: ben@comensal.org
Addition of aldosterone receptor
blocker to dual
renin–angiotensin–aldosterone
blockade leads to limitation of
tubulointerstitial injury of kidney
Kidney International (2007) 72, 1164–1165; doi:10.1038/sj.ki.5002511
To the Editor: The inhibition of the renin–angiotensin–
aldosterone system with angiotensin-converting enzyme
inhibitors and angiotensin II type 1 receptor blockers may
retard but not abrogate chronic kidney disease progression.1–3
Additional blockade of the aldosterone receptor as a way to
improve nephroprotection is suggested but not finally
proven.4 In the March issue of Kidney International, Kramer
et al. demonstrated, for the first time, remarkable reduction
in glomerulosclerosis and tubulointerstitial damage after
addition of spironolactone to angiotensin-converting enzyme
inhibitor treatment in proteinuria-induced renal damage
model in rats.5 Here, we present our recent clinical
observations on the same point. In randomized open
controlled crossover study on 18 patients with nondiabetic
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proteinuric chronic kidney disease with normal or slightly
impaired renal function, we evaluated the addition of
spironolactone 25 mg once daily to a combination treatment
with angiotensin-converting enzyme inhibitors, cilazapril and
angiotensin II type 1 receptor blocker, telmisartan with
maximal recommended doses on surrogate markers of
tubular damage and renal fibrosis. After 8 weeks of such
therapy, significant reductions of urine excretion of N-acetyl-
b-D-glucosaminidase by 36.3% (Po0.012), a1-microglobulin
by 27.9% (Po0.05), and N-terminal propeptide of type III
procollagen by 52.9% (Po0.016) were observed. These
beneficial renal effects may be due to decrease in proteinuria
observed simultaneously and direct nonhemodynamic con-
sequences of aldosterone antagonism including reduced
production of oxygen reactive species and prosclerotic
cytokines such as transforming growth factor-b-1, plasmino-
gen activator inhibitor type 1 as well as decrease macrophage
infiltration, processes involved in the development of
fibrosis.4 The results of Kramer et al. and those of our group
point toward a potential benefit of simultaneous blockade of
all components of renin–angiotensin system with the use of
an aldosterone receptor blocker on kidney outcome.
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